Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Farm. hosp ; 39(2): 71-79, mar.-abr. 2015. tab
Article in Spanish | IBECS | ID: ibc-135150

ABSTRACT

Objetivo: Elaborar una guía que recopile toda la información disponible en la bibliografía para el personal sanitario sobre la administración de medicamentos por vía subcutánea en pacientes de cuidados paliativos de la Unidad de Hospitalización a Domicilio. Método: Se diseña una tabla resumen de fármacos susceptibles de ser administrados por vía subcutánea en pacientes de cuidados paliativos mediante la revisión de los informes técnicos de los laboratorios fabricantes y de otra literatura publicada por organizaciones científicas, además de la búsqueda bibliográfica en Pubmed® y Micromedex®. Resultados: Se han revisado 65 fármacos y se ha elaborado una guía de recomendaciones en función de si existe información de su administración por vía subcutánea o, si por el contrario, esta contraindicado su uso. Conclusiones: Aunque mayoritariamente los laboratorios fabricantes no disponen de datos, la información recopilada en esta guía permitirá el manejo de la vía subcutánea de algunos de los medicamentos más utilizados en cuidados paliativos (AU)


Objective: Develop a guide that compiles all the information available in the literature for healthcare staff on the administration of drugs subcutaneously in palliative care patients of the Hospital Unit of home. Method: It is designed a summary table of drugs likely to be administered subcutaneously in palliative care patients through the revision of the technical reports of the manufacturers and other literature published by scientific organizations, in addition to the literature search on Pubmed® and Micromedex®. Results: We have reviewed 65 drugs and a guide has been developed of recommendations depending on whether there is information of his administration by subcutaneous or, if on the contrary, its use is contraindicated. Conclusions: Although mainly manufacturers laboratories do not have data, information collected in this guide will allow the management of the subcutaneous route of some of the most commonly used medications in palliative care (AU)


Subject(s)
Humans , Palliative Care/methods , Drug Utilization , Critical Illness/therapy , Injections, Subcutaneous/methods , Home Care Services, Hospital-Based , Terminally Ill , Pharmaceutical Services
2.
Farm Hosp ; 39(2): 71-9, 2015 Mar 01.
Article in Spanish | MEDLINE | ID: mdl-25817086

ABSTRACT

OBJECTIVE: Develop a guide that compiles all the information available in the literature for healthcare staff on the administration of drugs subcutaneously in palliative care patients of the Hospital Unit of home. METHOD: It is designed a summary table of drugs likely to be administered subcutaneously in palliative care patients through the revision of the technical reports of the manufacturers and other literature published by scientific organizations, in addition to the literature search on Pubmed® and Micromedex®. RESULTS: We have reviewed 65 drugs and a guide has been developed of recommendations depending on whether there is information of his administration by subcutaneous or, if on the contrary, its use is contraindicated. CONCLUSIONS: Although mainly manufacturers laboratories do not have data, information collected in this guide will allow the management of the subcutaneous route of some of the most commonly used medications in palliative care.


Objetivo: Elaborar una guía que recopile toda la información disponible en la bibliografía para el personal sanitario sobre la administración de medicamentos por vía subcutánea en pacientes de cuidados paliativos de la Unidad de Hospitalización a Domicilio. Método: Se diseña una tabla resumen de fármacos susceptibles de ser administrados por vía subcutánea en pacientes de cuidados paliativos mediante la revisión de los informes técnicos de los laboratorios fabricantes y de otra literatura publicada por organizaciones científicas, además de la búsqueda bibliográfica en Pubmed® y Micromedex®. Resultados: Se han revisado 65 fármacos y se ha elaborado una guía de recomendaciones en función de si existe información de su administración por vía subcutánea o, si por el contrario, esta contraindicado su uso. Conclusiones: Aunque mayoritariamente los laboratorios fabricantes no disponen de datos, la información recopilada en esta guía permitirá el manejo de la vía subcutánea de algunos de los medicamentos más utilizados en cuidados paliativos.


Subject(s)
Injections, Subcutaneous , Palliative Care/methods , Contraindications , Drug Therapy/methods , Guidelines as Topic , Home Care Services , Humans , Injections, Subcutaneous/methods
3.
Int J Clin Pharmacol Ther ; 52(6): 492-6, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24725443

ABSTRACT

BACKGROUND: Febrile neutropenia is a cause of dose reduction in hematological cancer treatments, with patient risk of infection proportional to duration and severity. In addition, colony-stimulating factors have been shown to be beneficial in a patient subgroup, although they are probably overused in the clinical setting. OBJECTIVE: Evaluation of compliance with American Society of Clinical Oncology 2006 criteria when it comes to filgrastim use in the Emergency Department of a Spanish general hospital. METHODS AND MATERIALS: A prospective observational study from August 2011 to February 2012 in a tertiary Spanish General Hospital. We included all patients prescribed with filgrastim in the Emergency Department. Data was collected on demographics, the pharmacotherapy history, the administered chemoprophylaxis, and the destination after discharge from a clinical department, the complete blood count, and the presence of fever >= 38 °C. RESULTS: 51 patients were recorded over the period of the study. 27.45% of prescriptions complied with the clinical practice guideline criteria given the risk of febrile neutropenia, whereas 72.34% of prescriptions did not comply with the criteria, 17.65% of which did not fulfil any requirements. CONCLUSIONS: A high percentage of colony-stimulating factors use in the Emergency Department does not comply with the medical practice guideline.


Subject(s)
Emergency Service, Hospital , Febrile Neutropenia/drug therapy , Granulocyte Colony-Stimulating Factor/therapeutic use , Hospitals, General , Hospitals, University , Immunologic Factors/therapeutic use , Practice Patterns, Physicians' , Drug Utilization Review , Emergency Service, Hospital/standards , Febrile Neutropenia/blood , Febrile Neutropenia/diagnosis , Filgrastim , Guideline Adherence , Hospitals, General/standards , Hospitals, University/standards , Humans , Inappropriate Prescribing , Practice Guidelines as Topic , Practice Patterns, Physicians'/standards , Prospective Studies , Recombinant Proteins/therapeutic use , Spain
SELECTION OF CITATIONS
SEARCH DETAIL
...